Abstract
Background Airway inflammation promotes bronchiectasis and lung injury in cystic fibrosis (CF). Amplification of inflammation underlies pulmonary exacerbations of disease. We asked whether sputum inflammatory biomarkers provide explanatory information on pulmonary exacerbations.
Patients and Methods We collected sputum from randomly chosen stable adolescents and adults and prospectively observed time to next exacerbation, our primary outcome. We evaluated relationships between potential biomarkers of inflammation, clinical characteristics and outcomes and assessed clinical variables as potential confounders or mediators of explanatory models. We assessed associations between the markers and time to next exacerbation using proportional hazard models adjusting for confounders.
Results We enrolled 114 patients, collected data on clinical variables [December 8, 2014 to January 16, 2016; 46% male, mean age 28 years (SD 12), mean percent predicted forced expiratory volume in 1 s (FEV1%) 70 (SD 22)] and measured 24 inflammatory markers. Half of the inflammatory markers were plausibly associated with time to next exacerbation. Age and sex were confounders while we found that FEV1% was a mediator.
Three potential biomarkers of RAGE axis inflammation were associated with time to next exacerbation while six potential neutrophil-associated biomarkers indicate associations between protease activity or reactive oxygen species with time to next exacerbation.
Conclusion Pulmonary exacerbation biomarkers are part of the RAGE proinflammatory axis or reflect neutrophil activity, specifically implicating protease and oxidative stress injury. Further investigations or development of novel anti-inflammatory agents should consider RAGE axis, protease and oxidant stress antagonists.
Tweetable abstract Sputum from 114 randomly chosen people with CF show RAGE axis inflammation, protease and oxidative stress injury are associated with time to next pulmonary exacerbation and may be targets for bench or factorial design interventional studies. (242 characters)
Competing Interest Statement
TGL, JAF, JLJ, YL, KAP and JBV received other support from the CFF (CC132-16AD, LIOU14Y0, LIOU14P0) and the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) (R01 HL125520) and received support during the current study for performing clinical trials from Abbvie, Calithera Biosciences, Corbus Pharmaceuticals, Gilead Sciences, Laurent Pharmaceuticals, Nivalis Therapeutics, Novartis, Proteostasis, Savara Pharmaceuticals, Translate Bio and Vertex Pharmaceuticals. FRA received additional other support from the NHLBI/NIH (R01 HL125520), the National Science Foundation (EMSW21-RTG) and the Margolis Foundation of Utah. PSB received other support from the CFF (Center and TDC grants) and the NHLBI/NIH (U01 HL114623) and received support for a clinical trial from Alcresta Therapeutics. BAC received other support from the CFF (C112-12, C112-TDC09Y, 10063SUB, 41339154.s132P010379SUB) and received support for clinical trials from Genentech, Novartis and Vertex Pharmaceuticals. CLD received other support from the CFF (C004-11, C004-TDC09Y, DAINES11Y3) and from the Health Resources and Services Administration (T72MC00012). JAF is now an employee of ICON plc, a clinical research organization involved in various trials pertinent to CF; She and ICON had no direct involvement in performance of the study following the change in affiliation. TH received other support from the CFF (PACE, Center Grant) and received support for clinical trials from Celtaxsys and Vertex Pharmaceuticals. JRH received other support from the NHLBI/NIH (HHSN268200900018C) and the Veterans Administration Healthcare System (I01 BX001533). JL received other support from the CFF (C017-11AF). CN received other support from the CFF (C138-12). PR received other support from the CFF (C003-12, C003-TDC09Y). SDS received other support from the CFF (AQUADEK12K1, SAGEL11CS0, GOAL13K2, NICK13A0, SAGEL14K1, NICK15R0) and the NHLBI/NIH (U54 HL096458) and the NCATS/NIH (Colorado CTSA Grant Number UL1 TR002535). JLT-C received other support from the CFF (TDC) and the NHLBI/NIH (HL103801) and received support for clinical trials from Vertex Pharmaceuticals. KNO is funded by the intramural research program of the NHLBI, NIH.
Clinical Protocols
https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-019-0705-0
Funding Statement
This project was supported by the CF Foundation (CFF) (LIOU13A0, LIOU14Y4), the National Center for Advancing Translational Science at the National Institutes of Health (NCATS/NIH 8UL1TR000105 [formerly UL1RR025764]), the Ben B and Iris M Margolis Foundation of Utah and the Claudia Ruth Goodrich Stevens Endowment Fund. Neither the project sponsors nor any sources of other support had direct roles in development and conduct of the study. None of the sponsors of clinical trials mentioned in the competing interests and other support section that follows participated in any way with this trial.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the University of Utah gave ethical approval for this work. The Institutional Review Board of St Luke's Health System gave ethical approval for this work. The Western Institutional Review Board for the Las Vegas CF Center gave ethical approval for this work. The Institutional Review Board of National Jewish Health gave ethical approval for this work. The Colorado Multiple Institutional Review Board for Children's Hospital Colorado gave ethical approval for this work. The Institutional Review Board of Phoenix Children's Hospital gave ethical approval for this work. The IRB of the University of Arizona gave ethical approval for this work. The Human Research Review Committee in the Human Research Protections Office of the University of New Mexico gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† In Memoriam: Dr. Barbara A Chatfield, August 25, 1959—October 8, 2016; Professor Sir David Roxbee Cox, July 15, 1924—January 18, 2022.
↵§ Authors are alphabetical except first (TGL), advisory committee (JPC, JSE, KNO) and senior (FRA).
(Liou, ted.liou{at}utah.edu; Helms, my.helms{at}hsc.utah.edu; Hoidal, john.hoidal{at}hsc.utah.edu ; and Jensen, judy.jensen{at}hsc.utah.edu; Packer, kristyn.packer{at}hsc.utah.edu; Paine, robert.paine{at}hsc.utah.edu; Vroom, jane.vroom{at}hsc.utah.edu; and Li, yanping.li{at}hsc.utah.edu);
(Liou; Asfour, fadi.asfour{at}hsc.utah.edu and Chatfield and Vroom);
(Argel, nargel{at}phoenixchildrens.com and Radford, peggy_radford{at}hotmail.com);
(Brown, perry.brown{at}fmridaho.org and Durham, durhamd{at}slhs.org);
(Daines, cdaines{at}email.arizona.edu and Molina, omolina{at}u.arizona.edu);
(Francis, jessicabakerfrancis{at}gmail.com);
(Glover, bglover1619{at}gmail.com; Nakamura, kerristrawberry{at}yahoo.com; and Yoshikawa, rmyoshika{at}gmail.com);
(Heynekamp, theynekamp{at}salud.unm.edu and Redway, ajredway{at}salud.unm.edu);
(Kartsonaki, christiana.kartsonaki{at}dph.ox.ac.uk);
(Keogh, ruth.keogh{at}lshtm.ac.uk);
(Kopecky, carol.kopecky{at}childrenscolorado.org and Sagel, scott.sagel{at}childrenscolorado.org);
(Lechtzin, nlechtz1{at}jhmi.edu);
(Lysinger, jlysinger{at}billingsclinic.org and Sprandel, ssprandel{at}billingsclinic.org);
(Poch, pochk{at}njhealth.org and Taylor-Cousar, taylor-cousarj{at}njhealth.org);
(Quittner, aquittner0202{at}gmail.com);
(Szczesniak, Rhonda.Szczesniak{at}cchmc.org);
(Clancy, john.clancy{at}cchmc.org);
(Elborn, s.elborn{at}qub.ac.uk);
(Olivier, olivierk{at}nhlbi.nih.gov);
(Adler, adler{at}math.utah.edu).
Data Availability
All data produced in the present study will be available upon reasonable request to the authors after peer-reviewed publication.
